未知生产厂商
Omburtamab is an anti-CD276 (B7-H3) antibody being investigated for use in various solid human tumours.
Omburtamab is an anti-CD276 (B7-H3) antibody being investigated for use in various solid human tumours.
CD276 (also known as B7-H3) is a member of the B7/CD28 immunoglobulin superfamily with possible co-stimulatory and co-inhibitory roles in T cell-mediated immunity. Despite low to absent expression on most healthy cells, CD276 is frequently highly expressed among solid human tumours. Omburtamab, a murine anti-B7-H3 antibody, and its humanized forms bind to the CD276 FG loop thought to be important in co-inhibitory functions. Omburtamab also facilitates direct antibody-directed cellular cytotoxicity (ADCC) of CD276-expressing tumour cells. Recent experiments using chimeric antigen receptor (CAR) T cells and bispecific killer cell engager (BiKE)-redirected natural killer cells demonstrated efficacy against NSCLC in vitro and in vivo. Hence, targeting CD276 appears to be an appealing option for overcoming immunotherapy blockade in solid tumours.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
